<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034458</url>
  </required_header>
  <id_info>
    <org_study_id>5992</org_study_id>
    <nct_id>NCT05034458</nct_id>
  </id_info>
  <brief_title>Diet in Pediatric CrohnÂ´s Disease Treated With Biologics</brief_title>
  <official_title>Diet as Adjuvant Therapeutics in the Era of Biologics in Pediatric-onset Crohn's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cded in remission patients with high calprotectin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the success of diet in achieving remission in mild-moderate forms of the disease, and&#xD;
      an increasing number of patients with loss of response to available drugs despite increasing&#xD;
      dose and pathophysiology of the disease, the aim of the present study is to evaluate whether&#xD;
      there is response with the addition of diet therapy in patients with moderate/severe forms of&#xD;
      CD receiving biologic therapy (infliximab or adalimumab) and presenting active disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with calprotectin less than 250 at week 12</measure>
    <time_frame>week 12</time_frame>
    <description>Number of participants who achieve normal fecal calprotectin after the diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of calprotectin</measure>
    <time_frame>week 12</time_frame>
    <description>To evaluate the change of the calprotectin value at 0 and 12 weeks in patients with or without the addition of dietary therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of patients that were able to continue the diet and not drop out during at least the 12 weeks of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will do biologic treatment and will do Crohns Disease Exclusion Diet for 12 weeks.They will be monitored periodically by interview and physical examination by physician and nutritionist, laboratory, fecal calprotectin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with normal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Crohn's disease exclusion diet</intervention_name>
    <description>Patients will receive, in addition to their normal treatment, polymeric formula + diet</description>
    <arm_group_label>Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age&#xD;
&#xD;
          -  With a diagnosis of CD&#xD;
&#xD;
          -  Who have completed remission induction with biologic therapy&#xD;
&#xD;
          -  Who are on maintenance biologic therapy&#xD;
&#xD;
          -  Present calprotectin values higher than the limit values established by the laboratory&#xD;
             (higher than 250 ug/g).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children who are unable to receive enteral dietary intake&#xD;
&#xD;
          -  Comorbidities affecting nutritional status and/or bone metabolism, growth or pubertal&#xD;
             development&#xD;
&#xD;
          -  Children already on special diets&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Orsi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria s Arcucci, m.d.</last_name>
    <phone>+5491151775637</phone>
    <email>maria.arcucci@hospitalitaliano.org.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maria arcucci</last_name>
      <phone>+5491151775637</phone>
      <email>maria.arcucci@hospitalitaliano.org.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>MARIA SOLEDAD ARCUCCI</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT05034458/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT05034458/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

